JP2016517857A5 - - Google Patents

Download PDF

Info

Publication number
JP2016517857A5
JP2016517857A5 JP2016509276A JP2016509276A JP2016517857A5 JP 2016517857 A5 JP2016517857 A5 JP 2016517857A5 JP 2016509276 A JP2016509276 A JP 2016509276A JP 2016509276 A JP2016509276 A JP 2016509276A JP 2016517857 A5 JP2016517857 A5 JP 2016517857A5
Authority
JP
Japan
Prior art keywords
optionally
alkyl
alkynyl
alkenyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016509276A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016517857A (ja
JP6388915B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2014/075257 external-priority patent/WO2014173241A1/en
Publication of JP2016517857A publication Critical patent/JP2016517857A/ja
Publication of JP2016517857A5 publication Critical patent/JP2016517857A5/ja
Application granted granted Critical
Publication of JP6388915B2 publication Critical patent/JP6388915B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016509276A 2013-04-26 2014-04-14 置換5−(3,5−ジメチルイソオキサゾール−4−イル)インドリン−2−オン Expired - Fee Related JP6388915B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2013/074780 2013-04-26
CN2013074780 2013-04-26
PCT/CN2014/075257 WO2014173241A1 (en) 2013-04-26 2014-04-14 Substituted5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones

Publications (3)

Publication Number Publication Date
JP2016517857A JP2016517857A (ja) 2016-06-20
JP2016517857A5 true JP2016517857A5 (enExample) 2017-06-01
JP6388915B2 JP6388915B2 (ja) 2018-09-12

Family

ID=51791046

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016509276A Expired - Fee Related JP6388915B2 (ja) 2013-04-26 2014-04-14 置換5−(3,5−ジメチルイソオキサゾール−4−イル)インドリン−2−オン

Country Status (12)

Country Link
US (2) US9393232B2 (enExample)
EP (1) EP2989096B1 (enExample)
JP (1) JP6388915B2 (enExample)
AU (1) AU2014256750B2 (enExample)
BR (1) BR112015027130A2 (enExample)
CA (1) CA2901083A1 (enExample)
EA (1) EA027139B1 (enExample)
HK (1) HK1217484A1 (enExample)
IL (1) IL240126A0 (enExample)
MX (1) MX366623B (enExample)
SG (1) SG11201506829XA (enExample)
WO (1) WO2014173241A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
MX2015007921A (es) 2012-12-21 2016-03-03 Zenith Epigenetics Corp Compuestos heterociclicos novedosos como inhibidores de bromodominio.
MX366703B (es) 2013-03-15 2019-07-22 Incyte Holdings Corp Heterociclos tricíclicos como inhibidores de la proteína bet.
CA2901083A1 (en) 2013-04-26 2014-10-30 Beigene, Ltd. Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
WO2015004534A2 (en) 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
CN105407888B (zh) 2013-06-21 2019-05-21 齐尼思表观遗传学有限公司 新双环溴结构域抑制剂
WO2015006193A1 (en) 2013-07-08 2015-01-15 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
JP6542212B2 (ja) 2013-07-31 2019-07-10 ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. ブロモドメイン阻害剤としての新規キナゾリノン
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
SI3674302T1 (sl) 2014-04-23 2023-07-31 Incyte Holdings Corporation 1h-pirolo(2,3-c)piridin-7(6h)-oni in pirazolo(3,4-c)piridin-7(6h)-oni kot zaviralci proteinov bet
ES2855225T3 (es) 2014-09-15 2021-09-23 Incyte Corp Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
CA2966298A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
CA2966303A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
WO2016092375A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Corp. Substituted heterocycles as bromodomain inhibitors
CN107406438B (zh) 2014-12-17 2021-05-14 恒翼生物医药科技(上海)有限公司 溴结构域的抑制剂
CN111662226B (zh) 2015-01-28 2022-03-18 中国科学院广州生物医药与健康研究院 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
CR20190027A (es) 2016-06-20 2019-05-16 Incyte Corp Formas sólidas cristalinas de un inhibidor de bet
EP3490553B1 (en) 2016-07-29 2024-08-28 Oncternal Therapeutics, Inc. Combination comprising an indolinone compound and its use in the treatment of lymphoma
GB201716392D0 (en) * 2017-10-06 2017-11-22 Glaxosmithkline Intellectual Property (No 2) Ltd Compounds
US11931343B2 (en) 2018-08-27 2024-03-19 Arcus Biosciences, Inc. CD73 inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
EP4457224A1 (en) * 2021-12-29 2024-11-06 BeiGene Switzerland GmbH Heterocyclic compounds
WO2025064918A1 (en) * 2023-09-20 2025-03-27 The Board Of Regents Of The University Of Texas System First-in-class phospho-brd4 inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420970D0 (en) 2004-09-21 2004-10-20 Smithkline Beecham Corp Novel triazoloquinoline compounds
KR101600634B1 (ko) * 2007-12-28 2016-03-07 미쓰비시 타나베 파마 코퍼레이션 항암제
EP2303841A1 (en) * 2008-07-14 2011-04-06 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
ES2652304T3 (es) 2009-11-05 2018-02-01 Glaxosmithkline Llc Compuesto de benzodiacepina novedoso
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
US9102677B2 (en) 2009-11-05 2015-08-11 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CN102656147A (zh) 2009-12-11 2012-09-05 霍夫曼-拉罗奇有限公司 可用作ampk调节剂的螺吲哚-环丙烷二氢吲哚酮
WO2011069298A1 (en) 2009-12-11 2011-06-16 F. Hoffmann-La Roche Ag Novel cyclopropane indolinone derivatives
EP2902030B1 (en) 2010-05-14 2016-09-14 Dana-Farber Cancer Institute, Inc. Thienotriazolodiazepine compounds for treating neoplasia
CN103180318B (zh) 2010-05-14 2017-05-10 达那-法伯癌症研究所 雄性避孕组合物以及使用方法
JP5844358B2 (ja) 2010-06-22 2016-01-13 グラクソスミスクライン エルエルシー ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012143436A1 (en) 2011-04-21 2012-10-26 Sanofi-Aventis Deutschland Gmbh Medicated module with lock ring
WO2012151512A2 (en) 2011-05-04 2012-11-08 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2968360B1 (en) 2013-03-14 2021-01-20 ConverGene LLC Quinolinone derivatives for the inhibition of bromodomain-containing proteins
US9102684B2 (en) 2013-03-27 2015-08-11 Boehringer Ingelheim International Gmbh Indolinone analogues
CA2901083A1 (en) 2013-04-26 2014-10-30 Beigene, Ltd. Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones

Similar Documents

Publication Publication Date Title
JP2016517857A5 (enExample)
JP7402549B2 (ja) Cxcr4阻害剤およびその使用
AU2018360854B2 (en) Modulators of the integrated stress pathway
JP2013512903A5 (enExample)
BR112020006780A2 (pt) moduladores do estimulador de genes do interferon (sting)
TW202210465A (zh) 用於在癌症治療中對不可標定之kras進行降解標定之新穎小分子
TW201927771A (zh) 可作為蛋白質調節劑之雜環醯胺及其使用方法
US20210363136A1 (en) Modulators of the integrated stress pathway
JP2016533379A5 (enExample)
BR112020008817B1 (pt) Compostos moduladores da via de estresse integrada referência cruzada a pedidos relacionados
BR112020008825A2 (pt) moduladores da via de estresse integrada
WO2019090085A1 (en) Modulators of the integrated stress pathway
BR112020008827A2 (pt) moduladores da via de estresse integrada
TR201816176T4 (tr) Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler.
RU2014145544A (ru) Солевая форма ингибитора гистон-метилтрансферазы ezh2 человека
JP2015532295A5 (enExample)
JP2016513137A5 (enExample)
CO2018005854A2 (es) Inhibidores de la proteína quinasa, método de preparación y uso médico de los mismos
JP2015534578A5 (enExample)
JP2017537164A (ja) リンパ腫の治療に使用されるヒストン脱アセチル化酵素阻害剤とベンダムスチンとの組み合わせ
EA201790088A1 (ru) Ингибиторы syk
TW201930286A (zh) 側氧哌嗪衍生物
US12304913B2 (en) Dihydropyrrolopyrazole derivative
JP2014518544A5 (enExample)
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака